Shigella vaccine - Emergent BioDefense Operations Lansing
Alternative Names: Dysentery vaccine - Emergent BioDefense Operations Lansing; Shigellosis vaccine - Emergent BioDefense Operations LansingLatest Information Update: 24 Oct 2021
At a glance
- Originator Emergent BioDefense Operations Lansing
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Shigella infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Shigella-infections in USA
- 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
- 23 Dec 2002 Clinical data from a media release have been added to the adverse events and Bacterial Infections immunogenicity section